To Our New Jersey Life Sciences Community:
Welcome to another edition of The Weekender.
Federal Research Bill Holds Promise for ‘Personalized Medicine’ in New Jersey
The House Energy and Commerce Committee unanimously approved the 21st Century Cures Act, 51-0. The legislation has earned rave reviews across New Jersey’s research community, as well as its biotechnology and pharmaceutical industries. They see its goals of increasing medical research funding and speeding the approval of new drugs and medical devices as essential to promoting therapies that will serve patients and promote the state’s biotech and pharma companies. Click here for the press release.
Innovation in New Jersey
Governor Christie makes innovation a national priority. In his opinion piece in the Wall Street Journal, entitled “My Plan to Raise Growth and Incomes,” he discusses the importance of innovation and R&D to spur economic growth and states, “It is this exact investment in basic R&D, in such areas as biomedical research, materials science and high-performance computing, delivered in large part through individual investigators at universities, that has laid the vital groundwork for so much innovation in America’s fastest-growing industries.”
New Jersey is the Location of Choice Once Again
Helsinn Therapeutics Inc., a BioNJ Member, has moved its U.S. headquarters to Iselin. Helsinn’s real estate firm, Transwestern, said “The technology features, location and accessibility to transportation were all key factors that allowed us to pinpoint this ideal space for Helsinn Therapeutics’ U.S. operations. The company’s relocation is representative of a larger trend in which pharmaceutical companies are continuing to choose New Jersey for offices that are more conducive to their evolving space needs.”
BioNJ Patient Member Selected as a BIO 2015 Everyday Superhero Finalist
Kathleen Arntsen, President and CEO of the Lupus and Allied Diseases Association, a BioNJ Member located in Verona, NY, who has been named a finalist for BIO’s Everyday Superheroes of Biotech competition. Kathleen was selected by popular vote as one of only five finalists in the Patient Group category. Congratulations, Kathleen!
Hurry and register for BIO 2015 if you haven’t already! We look forward to seeing you there!
Click here for this week’s Weekender.